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i 
Abstract 
 Mild cognitive impairment (MCI) is often a prodromal stage for Alzheimer’s disease 
(AD) development, with those diagnosed with MCI at increased risk for developing AD. The 
present study aimed to provide data to support a prodromal stage of MCI via analysis utilizing 
the neuropsychological domain of memory, subjective memory impairment (SMI), and the PET 
tau biomarker, AV-1451. It was hypothesized that individuals with SMI would differ 
significantly from participants without SMI (nSMI) on measures of memory and level of tau 
binding in the entorhinal cortices and the hippocampi. It was further hypothesized that 
differences in memory would be mediated by level (high/low) of binding in these 
neuroanatomical structures. The sample included 127 cognitively normal (CN) participants, 
selected from the Alzheimer’s Disease neuroimaging Initiative 3. Participants were cognitively 
normal, free from co-morbid disorders such as depression, and included individuals who had 
undergone PET imaging at baseline testing. Results found no significant differences between 
memory scores for SMI or nSMI participants, nor were there significant differences between 
groups on tau standardized uptake value ratios. There were significant main effects for tau level 
and location (left/right entorhinal cortices and left/right hippocampi) for the Wechsler Memory 
Scale-IV Logical Memory I test, and in the left entorhinal cortex for Logical Memory II. Current 
findings support differences in level of AV-1451 tau binding for story memory. The data 
provides a baseline for future researchers to utilize the cognitive measure of story memory in 
conjunction with tau level to develop a neuropsychological profile for individuals who may 
benefit from earlier intervention to slow progression of neurodegenerative decline.  
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CHAPTER I: INTRODUCTION AND LITERATURE SUPPORT 
Background and Problem Statement 
Mild cognitive impairment (MCI) is often a prodromal stage for Alzheimer’s disease 
(AD) development, with those diagnosed with MCI at increased risk for developing AD 
(Bruscoli & Lovestone, 2004; Petersen et al., 2001). While there is no cure for MCI or AD, 
research shows that earlier treatment intervention in patients with neurodegenerative disorders 
significantly slows progression (Doody, Geldmacher, Gordon, Perdomo, & Pratt, 2001; Nelson 
& Tabet, 2015; Vellas et al., 2011). Therefore, it follows that earlier detection of MCI would 
allow for earlier implementation of interventions and/or preventative medication to slow 
progression of neurodegeneration.  
Recent research on early stages of AD have discovered changes in cognitive domain-
specific areas before clinical diagnosis is made (Chen et al., 2001; Hamel et al., 2015). 
Specifically, Bäckman, Jones, Berger, Laukka, and Small (2005) completed a meta-analysis of 
47 studies with clinically normal and preclinical AD cases to determine which cognitive domains 
may be impacted ahead of diagnostically indicated neurocognitive decline. Their results found 
significant changes in nearly all cognitive domains (including episodic memory), though with 
sparing of primary memory, prior to AD diagnosis (per Bäckman et al., “primary memory” 
referred to the Digit Span–Forward subtest from the WAIS–R and the primary memory score 
from the lag method (Tulving & Colotla, 1970). The authors concluded that future research 
should incorporate their findings with biological data to help further understanding of the 
diagnostic utility of these preclinical domains. 
Operational Definitions 
Diagnosis of MCI (Petersen, 2004) requires a decline in neurocognitive function from a 
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premorbid level that does not negatively impact the ability of the person to complete activities of 
daily living (American Psychiatric Association, 2013). 
Neurodegeneration in the form of AD is marked by memory impairment and cognitive 
decline which impairs daily functioning (American Psychiatric Association, 2013). This is a 
deteriorative disorder with no known cure. Additionally, those with AD tend to have higher 
levels of tau and decreased levels of β-amyloid peptide (Aβ42; Lee, Goedert, & Trojanowski, 
2001; Murphy & LeVine, 2010).  
 There are myriad methods for defining subjective memory impairment (SMI), with many 
researchers using a variation of single self-report yes/no scaled questions (Abdulrab & Heun, 
2008). While there is no consensus on defining SMI for clinical or research purposes, this study 
will define SMI as an awareness of memory deficits in the patient as indicated by a “yes” 
response on question 10 of the Geriatric Depression Scale (“Do you feel you have more 
problems with memory than most?”). 
Biomarkers of Neurodegeneration in MCI and AD 
Biomarkers for tau tangles were originally assessed post mortem and broken in to stages 
per Braak & Braak (1991) criteria. Tau accumulation in Braak stages I and II relate to NFTs in 
the transentorhinal cortex within the left temporal lobe (Braak & Braak, 1995). Stages I and II 
relate to non-clinical presentations and are considered “prodromal” stages; that is, when some tau 
accumulation occurs, without clinical symptomatology. Stages III-IV involve the limbic system 
and identify incipient Alzheimer's disease. The neocortical stages (V-VI) classify fully developed 
Alzheimer's disease. Historically, Braak staging was determined via examination of sections of 
brain obtained after death, and thus implementation of staging during the disease’s progression 
was impossible. However, recently neuroimaging has allowed clinicians to apply Braak staging 
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via biomarkers assessed through imaging techniques such as positron emission tomography 
(PET) to provide a realistic and applicable means to asses for pathology of MCI and AD 
development in vivo (Braak, Alafuzoff, Arzberger, Kretzschmar, & Del Tredici, 2006).   
Tau biomarkers have been found to correlate well with decreases in functioning (Buckley 
et al., 2017; Vogel et al., 2017) and are a key focus of current neurodegenerative research. Tau is 
a protein within brain cells which assists in transportation of other proteins within neurons 
(Mandelkow & Mandelkow, 1994). Neurofibrillary tangles (NFT) are an intracellular 
accumulation of twisted tau protein fragments, resulting in poor or no transmission within 
microtubules, eventually leading to cell death. Simply, accumulation of tau tangles leads to death 
of brain cells and impaired functioning, and NFTs are a characteristic structural abnormality 
found in the brains of patients with AD (Dickson, 2004). Amyloid plaques are another common 
finding in patients with AD, which develops extracellularly, but is not normally produced outside 
of neurodegenerative processes (Murphy, & LeVine, 2010). However, biomarkers for tau have 
been shown to be more pathological for MCI versus cognitively normal (CN) patients (Eliassen 
et al., 2017). Specifically, tau is a stronger correlate of cognitive function than amyloid. 
Additionally, NFTs relate to normal aging and AD pathology, and binding of tau biomarkers are 
utilized in imaging assessment of neurodegeneration (Maass et al., 2017).    
Neuropsychological Correlates of Neurodegeneration and Tau 
Specific neuropsychological domains have been found to be more strongly correlated 
with impaired functioning and age progression. Specifically, episodic memory has shown myriad 
studies supporting deficits related to decline which is outside of the realm of normal aging 
(Ricci, Graef, Blundo, & Miller, 2012). Verbal and semantic fluency are widely used to assess 
for cognitive decline in older adults (Henry, Crawford, & Phillips, 2004), while executive 
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functioning is a hallmark measure of neuropsychological decline in older adults (Kirova, Bays, 
& Lagalwar, 2015), both within normal aging and patients with neurodegenerative disorders.  
A recent study by Digma, Madsen, Reas, Dale, Brewer, and Banks (2019) utilized 131 
amyloid-positive participants who underwent flortaucipir (FTP) PET, MRI, and 
neuropsychological testing to determine relationships between tau deposition and cognitive 
impairment. Their results found cognitive domains which correlated with tau deposition. 
Notably, they found a relationship between levels of tau via FTP and the cognitive domains of 
language fluency and aspects of visuospatial functioning; specifically, as performances on these 
tasks declined, the level of tau in various brain regions increased. The concluded that worse 
cognition was related to increased tau presence and cortical thinning in their patients. 
Additionally, Eckerström et al. (2013) found a specific memory task (Rey Auditory Verbal 
Learning test) in conjunction with level of tau accumulation was the strongest predictor of 
conversion to dementia.  
Thus, it is clear neuropsychological assessment is widely used to detect cognitive deficits 
and monitor decline in the aging population. Neuropsychological functioning has repeatedly 
been shown to accurately assess cognitive functioning and decline (Lezak, Howieson, Bigler, & 
Tranel, 2012). Specifically, individual performance on neuropsychological assessments of 
cognitive domains (memory, attention, language, executive functioning, visuospatial, and motor 
functioning) have repeatedly and consistently supported a direct relationship to functioning of 
each domain. Consequently, use of neuropsychological tools in assessing and monitoring MCI 
and AD development is not only beneficial, but crucial. Research has found a relationship 
between neuropsychological data and biomarkers (Engelborghs et al., 2006), though few have 
looked at the specific AV-1451 biomarker and neuropsychological functioning. Thus, one of the 
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aims of the current research focused on level of tau accumulation in the brain, and the impact it 
had on neuropsychological assessment of cognitive functioning. 
Subjective Memory Impairment 
The presence of SMI has been shown to be a possible early sign of MCI or AD 
development (Jessen et al., 2010), though limited research has been conducted which provides 
enough support for SMI presence alone to indicate need for a preventative medication regime in 
patients. Research shows individuals with normal neuropsychological functioning but with SMI 
show brain-based deficits in gray matter as compared to cognitively intact adults (Saykin et al., 
2006). Additionally, SMI within MCI populations relates to impaired neuropsychological 
functioning, specifically verbal episodic memory (Gifford et al., 2015). A strong predictor for 
transition to MCI is the presence of SMI (Reisberg & Gauthier, 2008), with various studies 
supporting MCI as a prodromal stage of AD (Geerlings, Jonker, Bouter, Ader, & Schmand, 
1999). Thus, recognition and understanding of the relationship between SMI and 
neuropsychological functioning, prior to development of MCI or AD (i.e. individuals with SMI 
only), can provide clinical and diagnostic information which may allow for earlier interventions, 
and result in slowed degeneration for individuals likely to develop MCI and AD. 
Purpose of the Study 
The current study focused on biomarker 18F-AV-1451 [(F-18)T807] (AV-1451) and its 
relationship to neuropsychological performances and subjective memory impairment. Biomarker 
AV-1451 via PET imaging has increased binding in MCI and AD patients (Cho et al., 2016), and 
binds to AD-specific tau throughout the brain (Das et al., 2018), with increased binding in the 
medial temporal lobe (Vemuri et al., 2017). Research looking at tau biomarkers in AD patients 
discovered AV-1451 as a biomarker of disease staging in AD, with increased binding found with 
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advanced stages of the disease (Mattsson et al., 2017). The current study’s purpose is to assist in 
earlier detection of cognitive decline, through utilization of SMI (“Do you feel you have more 
problems with your memory than others?), neuropsychological assessment, and level of AV-
1451 tau biomarker via PET imaging.  
Research Question I 
Does the presence of SMI in otherwise cognitively normal participants relate 
significantly to neuropsychological functioning? 
Hypotheses for Research Question I 
Executive functioning composite scores. There will not be a significant difference 
between SMI and no SMI (nSMI) participants on an executive functioning (EF) composite score.  
Trailmaking Test A. There will not be a significant difference between SMI and nSMI 
participants on Trail Making Test A scores.  
Trailmaking Test B. There will not be a significant difference between SMI and nSMI 
participants on Trail Making Test B scores.  
Clock drawing test. There will not be a significant difference between SMI and nSMI 
participants on clock drawing scores.  
Category fluency test. There will not be a significant difference between SMI and nSMI 
participants on category fluency scores.  
Memory composite scores. There will be a significant difference between SMI and 
nSMI participants on a memory composite score.  
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Rey Auditory Verbal Learning Test immediate recall. There will be a significant 
difference between SMI and nSMI participants in episodic memory, as measured by the Rey 
Auditory Verbal Learning test (RAVLT) immediate recall.  
Rey Auditory Verbal Learning Test delayed recall. There will be a significant 
difference between SMI and nSMI participants in episodic memory, as measured by the Rey 
Auditory Verbal Learning test (RAVLT) delayed recall.  
Wechsler Memory Scale-Fourth Edition Logical Memory I. There will be a 
significant difference between SMI and nSMI participants in episodic memory, as measured by 
the Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory I.  
Wechsler Memory Scale-Fourth Edition Logical Memory II. There will be a 
significant difference between SMI and nSMI participants in episodic memory, as measured by 
the WMS-IV Logical Memory II.  
Research Question II 
Does tau binding of AV-1451 in the left and right entorhinal cortices and the left and 
right hippocampi differ between participants with SMI and without SMI? 
Hypotheses for Research Question II 
Left entorhinal cortex AV-1451 binding. Participants with SMI will have increased 
binding of AV-1451 tau in the left entorhinal cortex.  
Right entorhinal cortex AV-1451 binding. Participants with SMI will have increased 
binding of AV-1451 tau in the right entorhinal cortex.  
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Left hippocampus AV-1451 binding. Participants with SMI will have increased binding 
of AV-1451 tau in the left hippocampus.  
Right hippocampus AV-1451 binding. Participants with SMI will have increased 
binding of AV-1451 tau in the left hippocampus.  
Research Question III 
Is there an interaction between AV-1451 tau binding and neuropsychologically-measured 
memory functioning, as mediated by SMI?  
Hypotheses for Research Question III 
Left entorhinal cortex tau level and memory composite score. When grouped by level 
(high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant differences 
between SMI and nSMI participants on memory composite scores.  
Right entorhinal cortex tau level and memory composite score. When grouped by 
level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant 
differences between SMI and nSMI participants on memory composite scores.  
Left hippocampus tau level and memory composite score. When grouped by level 
(high/low) of AV-1451 binding in the left hippocampus, there will be significant differences 
between SMI and nSMI participants on memory composite scores.  
Right hippocampus tau level and memory composite score. When grouped by level 
(high/low) of AV-1451 binding in the right hippocampus, there will be significant differences 
between SMI and nSMI participants on memory composite scores.  
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Left entorhinal cortex tau level and RAVLT immediate recall score. When grouped 
by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant 
differences between SMI and nSMI participants on RAVLT immediate recall scores.  
Right entorhinal cortex tau level and RAVLT immediate recall score. When grouped 
by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant 
differences between SMI and nSMI participants on RAVLT immediate recall scores.  
Left hippocampus tau level and RAVLT immediate recall score. When grouped by 
level (high/low) of AV-1451 binding in the left hippocampus, there will be significant 
differences between SMI and nSMI participants on RAVLT immediate recall scores.  
Right hippocampus tau level and RAVLT immediate recall score. When grouped by 
level (high/low) of AV-1451 binding in the right hippocampus, there will be significant 
differences between SMI and nSMI participants on RAVLT immediate recall scores.  
Left entorhinal cortex tau level and RAVLT delayed recall score.  When grouped by 
level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant 
differences between SMI and nSMI participants on RAVLT delayed recall scores.  
Right entorhinal cortex tau level and RAVLT delayed recall score. When grouped by 
level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant 
differences between SMI and nSMI participants on RAVLT delayed recall scores.  
Left hippocampus tau level and RAVLT delayed recall score. When grouped by level 
(high/low) of AV-1451 binding in the left hippocampus, there will be significant differences 
between SMI and nSMI participants on RAVLT delayed recall scores.  
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Right hippocampus tau level and RAVLT delayed recall score. When grouped by 
level (high/low) of AV-1451 binding in the right hippocampus, there will be significant 
differences between SMI and nSMI participants on RAVLT delayed recall scores.  
Left entorhinal cortex tau level and WMS-IV Logical Memory I score. When 
grouped by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be 
significant differences between SMI and nSMI participants on WMS-IV Logical Memory I 
scores.  
Right entorhinal cortex tau level and WMS-IV Logical Memory I score. When 
grouped by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be 
significant differences between SMI and nSMI participants on WMS-IV Logical Memory I 
scores.  
Left hippocampus tau level and WMS-IV Logical Memory I score. When grouped by 
level (high/low) of AV-1451 binding in the left hippocampus, there will be significant 
differences between SMI and nSMI participants on WMS-IV Logical Memory I scores.  
Right hippocampus tau level and WMS-IV Logical Memory I score. When grouped 
by level (high/low) of AV-1451 binding in the right hippocampus, there will be significant 
differences between SMI and nSMI participants on WMS-IV Logical Memory I scores.  
Left entorhinal cortex tau level and WMS-IV Logical Memory II score. When 
grouped by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be 
significant differences between SMI and nSMI participants on WMS-IV Logical Memory II 
scores.  
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Right entorhinal cortex tau level and WMS-IV Logical Memory II score. When 
grouped by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be 
significant differences between SMI and nSMI participants on WMS-IV Logical Memory II 
scores.  
Left hippocampus tau level and WMS-IV Logical Memory II score. When grouped 
by level (high/low) of AV-1451 binding in the left hippocampus, there will be significant 
differences between SMI and nSMI participants on WMS-IV Logical Memory II scores.  
Right hippocampus tau level and WMS-IV Logical Memory II score. When grouped 
by level (high/low) of AV-1451 binding in the right hippocampus, there will be significant 
differences between SMI and nSMI participants on WMS-IV Logical Memory II scores.  
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CHAPTER II: METHODS 
Participant Characteristics  
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003 
as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The 
primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can be combined to measure the progression of MCI ad AD. For 
up-to-date information, see www.adni-info.org. 
Participants for the current study were pulled from the Alzheimer’s Disease 
Neuroimaging Initiative-3 study (ADNI3; http://adni.loni.usc.edu/), created in 2016 to track 
progression of neurodegeneration. The ADNI3 study is a continuation of the original ADNI 
database which was created in 2004 for the purpose of earlier detection of AD, with the goal to 
utilize this information to support earlier intervention, prevention, and treatment of the disease. 
ADNI3 continues to focus on earlier detection of AD, through the addition of utilization of tau 
PET and functional imaging techniques, which were not included in the original ADNI studies. 
The ADNI3 study collects and utilizes data from various locations in the United States pertaining 
to cognitive impairment and AD, with the aim of better understanding its course and 
development. Participates in ADNI3 include males and females aged 55 to 90, across CN, MCI, 
and mild AD groups. Exclusion criteria for ADNI participants included any significant 
neurologic disease (i.e. Parkinson’s, Huntington’s, normal pressure hydrocephalus, brain tumor, 
progressive supranuclear palsy), contraindications for MRI and PET imaging (i.e. pacemaker, 
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metal fragments), and certain co-morbid diagnoses (i.e., schizophrenia, substance abuse, unstable 
medical conditions). For a full list of inclusion and exclusion criteria, and for up to date 
information, please visit the ADNI website (www.adni-info.org).  
Diagnostic Determination  
The criteria of CN, as defined by ADNI and subsequently utilized in this study, included 
participants (a) with or without SMI verified by a study partner, (b) with normal memory 
function as indicated by score cutoffs on the Logical Memory II subscale of the Wechsler 
Memory Scale-Revised (WMS-R), based on level of education, (c) with Mini-Mental Status 
Examination (MMSE) score between 24 and 30, (d) with Clinical Dementia Rating (CDR) score 
of 0, (e) with absence of significant impairment in cognitive functions or activities of daily 
living, and (f) with stability of medications for at least 4 weeks. For the purposes of the current 
study, anyone who obtained a score of 10 or higher on the Geriatric Depression Scale, indicating 
clinical levels of depression, were excluded.  
The current study included participants characterized by ADNI3 as CN, who completed a 
neuropsychological battery, the Geriatric Depression Scale (GDS), PET imaging, and 
apolipoprotein-ɛ4 (APOE) collection at a baseline study visit. One participant had a score of 10 
on the GDS indicating mild depression and was excluded from the study. APOE results were 
unavailable for two participants (both without SMI) and were therefore excluded. The final 
sample size consisted of 127 individuals (see Table 1 for demographic breakdown). All study 
procedures were approved by National Louis University’s Institutional Review Board prior to 
data access or analysis of data.  
The current sample included 127 participants without MCI or dementia (i.e. CN). 
Participants in this group were an average of 79 years of age (50% female) with 17 years of 
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education. 
Of the 127 participants, 20 individuals were classified as SMI. The SMI participants were 
an average age of 76 years of age (65%) females with 17 years of education. The remaining 107 
individuals were classified as nSMI group and had an average age of 79 years (48% female) and 
an average of 17 years of education (see Table 1). 
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Table 1. 
Demographic and Clinical Characteristics of Study Group 
Notes.  SD = standard deviation.  
                                                                Total (N = 127) SMI Group (n = 20) nSMI Group (n = 107) p-value 
Mean Age (SD), in years  79 (7) 76 (6) 79 (7) .08 
Mean Education (SD), in years  17 (2) 17 (2) 17 (3) .71 
Sex (%) 
Female 
 
64 (50.4%) 
 
 
13 (65.0%) 
 
51 (47.7%) .24 
Race/Ethnicity (%) 
   American Indian 
   African American 
   Asian, Pacific Islander 
   Caucasian  
   More than One Race 
 
 
1 (.8%) 
5 (3.9%) 
2 (1.6%) 
117 (92.1%) 
2 (1.6%) 
 
 
1 (5.0%) 
 
19 (95.0%) 
 
 
1 (.9%) 
4 (3.7%) 
2 (1.9%) 
98 (91.6%) 
2 (1.9%) 
.09 
APOE- ɛ4, % positive 30 40 28 .32 
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Cognitive Impairment Status 
The current study defined SMI as a complaint of memory difficulties, as indicated by a 
“yes” response on question 10 of the Geriatric Depression Scale (“Do you feel you have more 
problems with memory than most?”). Thus, participants with a “yes” response to this question 
were separated into the SMI group, while those with a “no” response were categorized as nSMI.  
Neuropsychological Assessment  
All participants completed a neuropsychological battery at baseline, which included the 
following measures/domains utilized in the current study:  
Executive functioning composite. Composite executive functioning (EF) scores were 
created previously by Gibbons et al. (2012) and utilized in the current study. Specifically, this 
composite score included total scores from the WAIS-R Digit Symbol Substitution, Digit Span 
Backwards, Trails A and B, Category Fluency, and Clock Drawing to create an overall 
composite score for EF. The EF Composite score was standardized to a z-score with a mean of 
zero and an SD of one. Thus, when interpreting, higher scores indicate better functioning, and 
lower EF composite scores indicate below average functioning. The range of EF composite 
scores fall along the same continuum as z-scores.   
Trail Making Test A & B. The Trail Making Test was originally constructed in 1938 
and consists of two separate tasks (Strauss, Sherman, & Spreen, 2006). Task A requires 
individuals to draw lines with a pencil to sequentially connect 25 encircled numbers which are 
randomly arranged on a page. Task B requires individuals to connect, by making pencil lines, 25 
encircled numbers and letters sequentially by alternating numbers and letters.  Each participant 
was instructed to complete a practice set before beginning the experimental set. Both tasks 
require attention, visual scanning, visuo-spatial memory, and working memory for the target 
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sequence. Task B requires increased working memory to keep two target sequences ready and 
reflects cognitive flexibility and the ability to maintain sets (Quinones et al., 2009). The Trail 
Making Test A (TMT A) and B (TMT B) have been shown to be significant predictors of decline 
from MCI to AD in conjunction with MRI and CSF biomarkers (Ewers et al., 2012). Scores are 
described and compared in seconds taken to complete the task, with higher scores (time) 
indicating worse performance.  
Category/semantic fluency. The category fluency task requires the participant to 
produce as many words as possible from a specific category provided by the examiner (Strauss et 
al., 2006). Each task produced a raw score based on raw number of words was produced by the 
participant in an allot amount of time. These raw scores were then converted to a standard score 
based on gender, age, and education. Category fluency, specifically animal naming, is widely 
used to asses for cognitive deficits in older adults (Henry et al., 2004).  
Clock drawing. Clock drawing is a measure of visuospatial, constructional, and 
executive function and is used as a clinical screener for dementia and executive dysfunction 
(Strauss et al., 2006). The clock drawing test is used as a clinical screener for dementia and 
executive dysfunction (Strauss et al., 2006). Scores on the clock drawing test utilize raw scores 
and range from 0 to 5, with higher scores indicating better performance (accurate placement and 
inclusion of all numbers, and accurate setting of the clock hands to a specific time).  
Episodic memory composite. A composite memory score was created by Crane et al. 
(2012) within the ADNI database and includes the Rey Auditory Verbal Learning test (RAVLT; 
2 versions), AD Assessment Schedule – Cognition (ADAS-Cog), Mini-Mental State 
Examination (MMSE), and the Wechsler Memory Scale - Fourth Edition (WMS-IV) Logical 
Memory I and II tests. The memory composite score was used as a measure of overall memory. 
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As above, the memory composite score was standardized to a z-score with a mean of zero and an 
SD of one. Thus, when interpreting, higher scores indicate better functioning, and lower memory 
composite scores indicate below average functioning. The range of memory composite scores 
fall along the same continuum as z-scores.   
Rey Auditory Verbal Learning Test. The Rey Auditory Verbal Learning Test 
(RAVLT) is widely used in assessing different forms of dementia (Ricci et al., 2012), providing 
support for utility of RAVLT as a measure of memory via auditory list learning. RAVLT 
performances are based on raw scores, utilizing the total number of words recalled by the 
participant for each trial. A higher number related to better performance.  
Wechsler Memory Scale Logical Memory Fourth Edition. The Wechsler Memory 
Scale- Fourth Edition (WMS-IV; Wechsler, 2009) is a series of memory tests designed to assess 
a participant’s auditory, verbal, visual, and working memory, and includes an “older adult” 
version for those over the age of 69. Within the WMS-IV, participants were administered 
Logical Memory I & II in which participants were required to listen to two short stories read by 
the examiner and then recall the narratives after a 20 - 30 min delay. WMS-IV Logical Memory I 
and II assess contextual verbal memory and have been found to be a strong tool for accurately 
assessing memory impairment (Lezak et al., 2012), and has shown specificity for episodic 
memory deficits (Rabin et al., 2009). Scoring for both WMS-IV Logical Memory tests was based 
on raw number of details recalled on two stories in combination across immediate and delayed 
trials. Higher scores across either Logical Memory I or Logical Memory II indicated better 
performance.  
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Biomarker Protocol 
Research conducted by Mishra et al. (2017) provides support for use of a partial-volume 
corrected tau-PET standardized uptake value ratios (SUVR) cut-off of 1.25 to separate CN adults 
into low and high tau groups. Mishra et al., 2017 used a bootstrapped sparse k-means analysis to 
determine the 1.25 SUVR cut off. The medial temporal region has been found to be the brain 
area most heavily impacted by tau accumulation after correcting for z-scores specific to each 
region of interest in their study (Vemuri et al., 2017).  
Verbal and visual memory have been found to be positively correlated with tau binding in 
the medial temporal regions (Cho et al., 2016). Specifically, poorer performance on tasks of 
verbal delayed recall from the MMSE related to higher accumulation of tau in the lateral and 
medial temporal and posterior cingulate cortices. As well, visual delayed recall on the RCFT 
related to higher levels of tau accumulation in lateral and medial temporal and posterior cingulate 
cortices for older adults with MCI and AD (Cho et al., 2016).  
Thus, the current study utilized the cut off 1.25 for SUVR raw scores as per Mishra et al., 
2017 to categorize participants into low (≤1.2499) and high (≥1.2500) tau groups, based on tau 
accumulation in the medial temporal lobes. Specifically, the right and left entorhinal cortices, as 
well as the left and right hippocampi, were assessed as regions of interest in how tau 
accumulation in these regions relates to cognitive functioning.  
Statistical Analyses 
Prior to all analyses, demographic data was compared to assess for any differences in 
groups for the following factors: age, gender, ethnicity, education level, and APOE ɛ4 status 
(status: positive = ɛ2/ ɛ4, ɛ3/ ɛ4, ɛ4/ ɛ4; negative = ɛ2/ ɛ2, ɛ2/ ɛ3, ɛ3/ ɛ3). Each of these variables 
(age, gender, ethnicity, education level, and APOE ɛ4 status) were included in subsequent 
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analyses to control for possible confounding factors and individual differences. Specifically, a 
chi-square test for independence was run to assess differences between SMI and nSMI for 
gender, ethnicity, and APOE ɛ4 status. An independent samples t-test was run to determine any 
differences between SMI and nSMI for age and education.   
Research Question I 
Does the presence of SMI in otherwise cognitively normal patients relate significantly to 
neuropsychological functioning? 
Analyses for Research Question I 
Executive functioning composite scores. A one-way Analysis of Covariance 
(ANCOVA) was run, with SMI and nSMI as categorical independent variables and EF 
composite score as the dependent variable. Gender, age, ethnicity, education, and APOE status 
were used as covariates to control for individual differences. 
Trail Making Test A. A one-way ANCOVA was run with SMI and nSMI as categorical 
independent variables and Trails A score as the dependent variable. Gender, age, ethnicity, 
education, and APOE status were used as covariates to control for possible individual 
differences. 
Trail Making Test B.  A one-way ANCOVA was run with SMI and nSMI as categorical 
independent variables and Trails B score as the dependent variable. Gender, age, ethnicity, 
education, and APOE status were used as covariates to control for individual differences.  
Clock drawing test. A one-way ANCOVA was run with SMI and nSMI as categorical 
independent variables and clock drawing score as the dependent variable. Gender, age, ethnicity, 
education, and APOE status were used as covariates to control for individual differences. 
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Category fluency test. A one-way ANCOVA was run with SMI and nSMI as categorical 
independent variables and category fluency score as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Memory composite scores. A one-way ANCOVA was run, with SMI and nSMI as 
categorical independent variables and memory composite score as the dependent variable. 
Gender, age, ethnicity, education, and APOE status were used as covariates to control for 
individual differences. 
Rey Auditory Verbal Learning Test immediate recall. A one-way ANCOVA was run 
with SMI and nSMI as categorical independent variables and RAVLT immediate recall score as 
the dependent variable. Gender, age, ethnicity, education, and APOE status were used as 
covariates to control for individual differences. 
Rey Auditory Verbal Learning Test delayed recall. A one-way ANCOVA was run 
with SMI and nSMI as categorical independent variables and RAVLT delayed recall score as the 
dependent variable. Gender, age, ethnicity, education, and APOE status were used as covariates 
to control for individual differences. 
Wechsler Memory Scale-Fourth Edition Logical Memory I. A one-way ANCOVA 
was run with SMI and nSMI as categorical independent variables and WMS-IV Logical Memory 
I score as the dependent variable. Gender, age, ethnicity, education, and APOE status were used 
as covariates to control for individual differences. 
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Wechsler Memory Scale-Fourth Edition Logical Memory II. A one-way ANCOVA 
was run with SMI and nSMI as categorical independent variables and WMS-IV Logical Memory 
II score as the dependent variable. Gender, age, ethnicity, education, and APOE status were used 
as covariates to control for individual differences. 
Research Question II 
Does tau binding of AV-1451 in the left and right entorhinal cortices and the left and right 
hippocampi differ between participants with SMI and without SMI? 
Analyses for Research Question II 
Left entorhinal cortex AV-1451 binding. A one-way ANCOVA was run with SMI and 
nSMI as categorical independent variables and left entorhinal tau standardized uptake value 
ratios (SUVR) as the dependent variable. Gender, age, ethnicity, education, and APOE status 
were used as covariates to control for individual differences. 
Right entorhinal cortex AV-1451 binding. A one-way ANCOVA was run with SMI 
and nSMI as categorical independent variables and right entorhinal tau SUVR as the dependent 
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control 
for individual differences. 
Left hippocampus AV-1451 binding. A one-way ANCOVA was run with SMI and 
nSMI as categorical independent variables and left hippocampus SUVR as the dependent 
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control 
for individual differences. 
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Right hippocampus AV-1451 binding. A one-way ANCOVA was run with SMI and 
nSMI as categorical independent variables and right hippocampus SUVR as the dependent 
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control 
for individual differences. 
Research Question III 
Is there an interaction between AV-1451 tau binding and neuropsychologically-measured 
memory functioning, as mediated by SMI?  
Analyses for Research Question III 
Left entorhinal cortex tau level and memory composite score. A two-way ANCOVA 
was run, with tau level in the left entorhinal cortex and SMI group as independent variables, and 
memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE 
status were used as covariates to control for individual differences.  
Right entorhinal cortex tau level and memory composite score. A two-way ANCOVA 
was conducted, with tau level in the right entorhinal cortex and SMI group as independent 
variables, and memory composite as the dependent variable. Gender, age, ethnicity, education, 
and APOE status were used as covariates to control for individual differences.  
Left hippocampus tau level and memory composite score. A two-way ANCOVA was 
conducted, with tau level in the left hippocampus and SMI group as independent variables, and 
memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE 
status were used as covariates to control for individual differences. 
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Right hippocampus tau level and memory composite score. A two-way ANCOVA 
was conducted, with tau level in the right hippocampus and SMI group as independent variables, 
and memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE 
status were used as covariates to control for individual differences. 
Left entorhinal cortex tau level and RAVLT immediate recall score. A two-way 
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as 
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Right entorhinal cortex tau level and RAVLT immediate recall score. A two-way 
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as 
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences.  
Left hippocampus tau level and RAVLT immediate recall score. A two-way 
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent 
variables, and RAVLT immediate recall as the dependent variable. Gender, age, ethnicity, 
education, and APOE status were used as covariates to control for individual differences.  
Right hippocampus tau level and RAVLT immediate recall score. A two-way 
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as 
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age, 
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ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Left entorhinal cortex tau level and RAVLT delayed recall score.  A two-way 
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as 
independent variables, and RAVLT delayed recall as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Right entorhinal cortex tau level and RAVLT delayed recall score. A two-way 
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as 
independent variables, and RAVLT delayed recall as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences.  
Left hippocampus tau level and RAVLT delayed recall score. A two-way ANCOVA 
was conducted, with tau level in the left hippocampus and SMI group as independent variables, 
and RAVLT delayed recall as the dependent variable. Gender, age, ethnicity, education, and 
APOE status were used as covariates to control for individual differences.  
Right hippocampus tau level and RAVLT delayed recall score. A two-way ANCOVA 
was conducted, with tau level in the right hippocampus and SMI group as independent variables, 
and RAVLT delayed recall as the dependent variable. Gender, age, ethnicity, education, and 
APOE status were used as covariates to control for individual differences.  
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Left entorhinal cortex tau level and WMS-IV Logical Memory I score. A two-way 
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as 
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender, 
age, ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Right entorhinal cortex tau level and WMS-IV Logical Memory I score. A two-way 
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as 
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender, 
age, ethnicity, education, and APOE status were used as covariates to control for individual 
differences.  
Left hippocampus tau level and WMS-IV Logical Memory I score. A two-way 
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent 
variables, and WMS-IV Logical Memory I score as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Right hippocampus tau level and WMS-IV Logical Memory I score. A two-way 
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as 
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender, 
age, ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Left entorhinal cortex tau level and WMS-IV Logical Memory II score. A two-way 
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as 
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independent variables, and WMS-IV Logical Memory II score as the dependent variable. 
Gender, age, ethnicity, education, and APOE status were used as covariates to control for 
individual differences. 
Right entorhinal cortex tau level and WMS-IV Logical Memory II score. A two-way 
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as 
independent variables, and WMS-IV Logical Memory II score as the dependent variable. 
Gender, age, ethnicity, education, and APOE status were used as covariates to control for 
individual differences.  
Left hippocampus tau level and WMS-IV Logical Memory II score. A two-way 
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent 
variables, and WMS-IV Logical Memory II score as the dependent variable. Gender, age, 
ethnicity, education, and APOE status were used as covariates to control for individual 
differences. 
Right hippocampus tau level and WMS-IV Logical Memory II score. A two-way 
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as 
independent variables, and WMS-IV Logical Memory II score as the dependent variable. 
Gender, age, ethnicity, education, and APOE status were used as covariates to control for 
individual differences. The Benjamini-Hochburg method (B-H; Benjamini & Hochberg, 1995), 
which controlled for a false discovery rate of α = .05, was utilized as a method of controlling for 
Type I error, while also circumventing Type II errors (false discovery). All p-values were ranked 
from smallest to largest and compared to B-H critical values. The largest p value which was 
smaller than the B-H critical value (and all subsequently smaller p-values) were considered 
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statistically significant. Thus, analyses were only considered significant when their p-value was 
less than .005. 
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CHAPTER III: RESULTS 
Assumptions 
Preliminary analyses were performed for all variables to ensure no violation of the 
assumptions of level of measurement, random sampling, independence of observation, 
normal distribution, and homogeneity of variance. Each of the dependent variables were 
continuous variables. After review of the dependent variables and their relationship with each 
other, independence of observation was met for each measure.  
Normality was assessed via values of skewness and kurtosis. Table 2 displays 
violations of the assumption of normality for dependent variables. When assessing skewness 
and kurtosis for normality, a nonparametric test may be used in place of a parametric test (i.e. 
ANOVA). However, no nonparametric test exists to replace ANCOVA analyses; that is, 
there is not a reliable nonparametric test which controls for covariates in the analysis. Per 
Stevens (2012), “skewness has only a slight effect (generally only a few hundredths) on the 
alpha level or power” and “the effects of kurtosis on level of significance, although greater, 
also tend to be slight” (p. 224). Thus, ANCOVA analyses were run, with assumptions 
specific to ANCOVAs assessed for each analysis (see below for detailed information for 
each variable), and strict significance value used to circumvent Type I and Type II error. 
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Table 2. 
Normality of variables 
Variable Min Max Skewness Kurtosis Kolmogorov-
Smirnov 
Sig. 
EF Composite -.81 2.99 .19 -.39 .09 .023* 
Trials A 15.00 65.00 .86 .67 .10 .004* 
Trails B 31.00 220.00 1.87 4.34 .18 .000* 
Clock 3.00 5.00 -2.03 3.43 .48 .000* 
Category Fluency 12.00 55.00 1.73 7.74 .11 .002* 
Memory Composite -.16 .79 .70 .91 .08 .069 
RAVLT Immediate 0.00 15.00 -.25 -.58 .10 .006* 
RAVLT Delay 0.00 15.00 -.20 -.69 .07 .089 
WMS-IV LM I 4.00 25.00 -.41 3.40 .08 .044* 
WMS-IV LM II 4.00 25.00 -.33 .34 .10 .008* 
EF= Executive Functioning; WMS-IV = Wechsler Memory Scale- Fourth Edition; 
LM=Logical Memory; RAVLT = Rey Auditory Verbal Learning Test; Trails = Trail Making 
Test; *p < 0.05 
 
EF Composite. 
Normality was assessed for the continuous outcome variable of EF Composite (M = 
1.09, SD = .08). Using the 5% trimmed mean (1.08) compared to the original mean (1.09), it 
was determined that there were not any extreme values influencing the mean of the data. The 
value for skew (.19) indicated normal distribution as it was far from 1.00. The value for 
kurtosis (-.39) did not indicate abnormal distribution. The K-S value (K-S = .09; p = .02) was 
significant, however review of a histogram supported a normal distribution of scores on the 
EF Composite (see Figure 1). Furthermore, a boxplot of the scores indicated there were no 
outliers (see Figure 2). After running the one-way between-groups ANCOVA, homogeneity 
of variance was assessed using Levene’s statistic (p = .40), and it was determined that the 
homogeneity of variance assumption was not violated because it was greater than the p > .05 
cut-off value. 
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Figure 1. Histogram showing distribution of EF Composite for the total sample 
 
Figure 2. Boxplot showing outliers of Executive Function Composite for the total sample 
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Trail Making A. 
Normality was assessed for the continuous outcome variable Trail Making A (M = 
30.83, SD = 9.53). Using the 5% trimmed mean (30.27) compared to the original mean 
(30.83), it was determined that there were not any extreme values influencing the mean of the 
data. The value for skew (.86) indicated possible abnormal distribution. The value for 
kurtosis (.67) also indicated possible abnormal distribution. The K-S value (K-S = .10; p = 
.004) was significant, suggesting that the distribution was abnormal. A histogram confirmed 
a positively skewed distribution of scores (see Figure 3), with review of a boxplot of the 
scores identifying 3 possible outliers which may be impacting distribution of this variable 
(see Figure 4). After running the one-way between-groups ANCOVA, homogeneity of 
variance was assessed using Levene’s statistic (p = .93), and it was determined that the 
homogeneity of variance assumption was not violated because it was greater than the p > .05 
cut-off value. 
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Figure 3. Histogram showing distribution of Trails A for the total sample 
 
 
Figure 4. Boxplot showing outliers of Trails A for the total sample 
Trail Making B. 
Normality was assessed for the continuous outcome variable of Trail Making B (M = 
73.91, SD = 33.70). Using the 5% trimmed mean (70.21) compared to the original mean 
(73.91), it was determined that there may be values influencing the mean of the data. The 
value for skew (1.87) and kurtosis (4.34) indicated abnormal distribution. The K-S value (K-
S = .18; p = .000) was significant, suggesting that the distribution was abnormal. A histogram 
confirmed the abnormal distribution of scores (Figure 5) and a boxplot of the scores indicated 
outliers (see Figure 6). After running the one-way between-groups ANCOVA, homogeneity 
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of variance was assessed using Levene’s statistic (p = .82), and it was determined that the 
homogeneity of variance assumption was not violated. 
 
Figure 5. Histogram showing distribution of Trails B for the total sample 
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Figure 6. Boxplot showing outliers of Trails B for the total sample 
Clock. 
Normality was assessed for the continuous outcome variable of clock (M = 4.78, SD 
= .47). Using the 5% trimmed mean (4.84) compared to the original mean (4.78), it was 
determined that there were not any extreme values influencing the mean of the data. The 
value for skew (-2.03), kurtosis (3.43), and the K-S value (K-S = .48; p = .000) suggest the 
distribution was abnormal. A histogram confirmed the normal distribution of scores on the 
clock were negatively skewed (see Figure 7). After running the one-way between-groups 
ANCOVA, homogeneity of variance was assessed using Levene’s statistic (p = .58), and it 
was determined that the homogeneity of variance assumption was not violated. 
 
 
Figure 7. Histogram showing distribution of clock scores for the total sample 
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Category Fluency Test. 
Normality was assessed for the continuous outcome variable of Category Fluency test 
(M = 21.99, SD = 5.79). Using the 5% trimmed mean (21.63) compared to the original mean 
(21.99), it was determined that there were not any extreme values influencing the mean of the 
data. The value for skew (1.73) and kurtosis (7.74) indicated abnormal distribution. The K-S 
value (K-S = .11; p = .002) was significant, suggesting that the distribution was abnormal. A 
histogram confirmed the positive skew of scores on the Category Fluency Test (see Figure 
8). Furthermore, a boxplot of the scores indicated there were two possible outliers (see Figure 
9). After running the one-way between-groups ANCOVA, homogeneity of variance was 
assessed using Levene’s statistic (p = .995), and it was determined that the homogeneity of 
variance assumption was not violated because it was greater than the p > .05 cut-off value. 
 
Figure 8. Histogram showing distribution of category fluency for the total sample 
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Figure 9. Boxplot showing outliers of category fluency recall 
Memory Composite. 
Normality was assessed for the continuous outcome variable of the memory 
composite score (M = 1.01, SD = .58). Using the 5% trimmed mean (.992) compared to the 
original mean (1.01), it was determined that there were not any extreme values influencing 
the mean of the data. The value for skew (.70) indicated normal distribution. The value for 
kurtosis (.91) indicated possible abnormal distribution. The K-S value (K-S = .08; p = .069) 
was not significant, suggesting that the distribution was normal. A histogram confirmed the 
normal distribution of scores on the Category Fluency Test (see Figure 10). A boxplot of the 
scores indicated there 2 possible outliers which likely related to possible kurtosis findings 
(see Figure 11). After running the one-way between-groups ANCOVA, homogeneity of 
variance was assessed using Levene’s statistic (p = .383) and it was determined that the 
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homogeneity of variance assumption was not violated because it was greater than the p > .05 
cut-off value.  
 
 
Figure 10. Histogram showing distribution of memory composite for the total sample 
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Figure 11. Boxplot showing outliers of memory composite 
 
RAVLT Immediate Recall. 
Normality was assessed for the continuous outcome variable of RAVLT Immediate 
Recall (M = 9.67, SD = 3.42). Using the 5% trimmed mean (9.76) compared to the original 
mean (9.67), it was determined that there were not any extreme values influencing the mean 
of the data. The value for skew (-.25) indicated normal distribution due to it being far from 
1.00. The value for kurtosis (-.58) did not indicate abnormal distribution. The K-S value (K-S 
= .10; p = .006) was significant, suggesting that the distribution may be abnormal. A 
histogram confirmed a negatively skewed distribution of scores on RAVLT Immediate 
Recall scores (see Figure 12). However, a boxplot of the scores indicated there were no 
outliers (see Figure 13). After running the one-way between-groups ANCOVA, homogeneity 
of variance was assessed using Levene’s statistic (p = .142), and it was determined that the 
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homogeneity of variance assumption was not violated because it was greater than the p > .05 
cut-off value. 
 
 
Figure 12. Histogram showing distribution of RAVLT immediate recall for the total sample 
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Figure 13. Boxplot showing outliers of RAVLT immediate recall 
RAVLT Delay Recall. 
Normality was assessed for the continuous outcome variable of RAVLT Delayed 
Recall (M = 8.17, SD = 4.05). Using the 5% trimmed mean (8.24) compared to the original 
mean (8.17), it was determined that there were not any extreme values influencing the mean 
of the data. The value for skew (-.20) indicated normal distribution. The value for kurtosis (-
.69) did not indicate abnormal distribution. The K-S value (K-S = .07; p = .089) was not 
significant, suggesting that the distribution was normal. A histogram confirmed the normal 
distribution of scores on the Category Fluency Test (see Figure 15). Furthermore, a boxplot 
of the scores indicated there were no outliers (see Figure 16). After running the one-way 
between-groups ANCOVA, homogeneity of variance was assessed using Levene’s statistic 
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(p = .132) and it was determined that the homogeneity of variance assumption was not 
violated because it was greater than the p > .05 cut-off value. 
 
Figure 14. Histogram showing distribution of RAVLT delay recall for the total sample 
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Figure 15. Boxplot showing outliers of RAVLT delay recall 
LM Immediate Recall. 
Normality was assessed for the continuous outcome variable of WMS-IV Logical 
Memory Immediate Recall (M = 15.89, SD = 3.47). Using the 5% trimmed mean (15.98) 
compared to the original mean (15.89), it was determined that there were not any extreme 
values influencing the mean of the data. The value for skew (-.41) indicated normal 
distribution and the value for kurtosis (.34) did not indicate abnormal distribution. The K-S 
value (K-S = .08; p = .044) was significant, suggesting that the distribution may be abnormal. 
A histogram confirmed a normal distribution of scores on the WMS-IV Logical Memory 
Immediate Recall (see Figure 16). A boxplot of the scores indicated there were 2 possible 
outliers (see Figure 17). After running the one-way between-groups ANCOVA, homogeneity 
of variance was assessed using Levene’s statistic (p = .343) and it was determined that the 
homogeneity of variance assumption was not violated because it was greater than the p > .05 
cut-off value. 
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Figure 16. Histogram showing distribution of WMS-IV immediate recall for the total sample 
 
Figure 17. Boxplot showing outliers of WMS-IV Logical memory immediate recall 
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LM Delay Recall. 
Normality was assessed for the continuous outcome variable of WMS-IV Logical 
Memory Delay Recall (M = 14.69, SD = 3.70). Using the 5% trimmed mean (14.79) 
compared to the original mean (14.69), it was determined that there were not any extreme 
values influencing the mean of the data. The value for skew (-.33) indicated normal 
distribution due to it being far from 1.00. The value for kurtosis (.34) did not indicate 
abnormal distribution. The K-S value (K-S = .10; p = .008) was significant, suggesting a 
possibly abnormal distribution. Review of a histogram confirmed a normal distribution of 
scores on the WMS-IV Logical Memory Delay Recall (see Figure 18). A boxplot of the 
scores indicated there 2 possible outliers (see Figure 19). After running the one-way 
between-groups ANCOVA, homogeneity of variance was assessed using Levene’s statistic 
(p = .076) and it was determined that the homogeneity of variance assumption was not 
violated because it was greater than the p > .05 cut-off value. 
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Figure 18. Histogram showing distribution of WMS-IV delay recall for the total sample 
 
Figure 19. Boxplot showing outliers of WMS-IV Logical memory delay recall 
Participant Characteristics. 
A chi-square test for independence indicated no significant association between SMI 
and nSMI for gender, χ2 (1, N = 125) = 1.39, p = .24, phi = .13, ethnicity, χ2 (1, N = 125) = 
1.04, p = .90, phi = .09, or APOE ɛ4 status, χ2 (1, N = 125) = 1.04, p = .31, phi = .09.  
An independent samples t-test indicated no significant difference between SMI and 
nSMI for age, t(123) = 1.79, p = .08, with a small effect size (η2 = .03).  
An independent samples t-test indicated no significant difference between SMI and 
nSMI for level of education t(123) = -.37, p = .71, with a small effect size (η2 = .001).   
Analyses by research question 
Research Question I: Subjective Memory Impairment and Cognitive Measures 
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One-way analyses of covariance (ANCOVAs) were run to compare SMI to nSMI on 
each cognitive neuropsychological measure (EF composite score, Trails A, Trials B, clock 
drawing, category fluency, memory composite score, RAVLT immediate recall, RAVLT 
delayed recall, WMS-IV Logical Memory I and WMS-IV Logical Memory II). For the 
current study, each possible covariate was included in every analysis in attempt to reduce the 
impact of confounding factors. Building a model that included all covariates increased 
robustness and decreased the possibility of Type 1 error. Levene’s tests and normality checks 
were carried out and the assumptions met for each analysis.  
Detailed information, including mean scores by group for all variables and statistical 
findings, is provided in Table 3. 
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Table 3. 
SMI (n = 20) versus nSMI (n = 107) for Neuropsychological Domains, SUVR, and Analyses 
 SMI nSMI F df ηp2 p 
Executive Function Domain       
EF Composite Score 0.83 (.68) 1.13 (.90) 4.04 115 .06 .007 
Trails A 31.20 (8.61) 30.76 (9.73) 1.31 114 .01 .255 
Trails B 81.05 (25.47) 72.55 (34.99) 3.39 113 .03 .068 
Clock Drawing 4.80 (.41) 4.77 (.48) 0.00 114 .00 .962 
Category Fluency 20.60 (4.83) 22.25 (5.93) 3.80 115 .03 .054 
Memory Domain       
Memory Composite Score 1.15 (.66) .99 (.56) .03 114 .00 .866 
RAVLT Immediate Recall 10.68 (3.32) 9.49 (3.42) 1.04 114 .01 .309 
RAVLT Delayed Recall 9.15 (4.27) 7.93 (4.01) .43 115 .00 .516 
WMS-IV LM I 15.55 (3.94) 15.95 (3.40) .45 115 .00 .505 
WMS-IV LM II  14.25 (3.89) 14.77 (3.68) .61 115 .01 .436 
Tau Measurements       
Left Entorhinal Tau SUVR 1.11 (.19) 1.11 (.12) .02 115 .00 .886 
Right Entorhinal Tau SUVR 1.09 (.14) 1.11 (.14) .02 115 .00 .886 
Left Hippocampus Tau 
SUVR 1.22 (.21) 1.21 (.15) 
.16 115 .00 .689 
Right Hippocampus Tau 
SUVR 1.22 (.19) 1.21 (.16) 
.150 115 .00 .701 
Note. Mean (SD); df = degrees of freedom, ηp2 = partial eta squared effect size, * = significant at 
the .005 level.
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Executive function domains. There was not a significant difference between SMI and 
nSMI participants on EF composite scores (F(1, 115) = 4.04, p = .007, ηp2 = .06) when 
controlling for B-H. While not statistically significant, the estimated marginal means for 
participants with SMI (M = .40) were lower scores than composite score for the nSMI group (M 
= .90) after adjusting for the covariates. Figure 21 shows EF scores by group.    
he ANCOVA comparing SMI and nSMI indicated no significant differences on Trails A (F(1, 
114) = 1.31, p = .255, ηp2 = .01); Trails B (F(1, 113) = 3.39, p = .068, ηp2 = .03); clock drawing, 
(F(1, 114) = .00, p = .962, ηp2 = .00); or category fluency (F(1, 115) = 3.80, p = .054, ηp2 = .03). 
When comparing the estimated marginal means, participants with SMI had higher Trails A (M = 
38.17) and Trails B (M = 98.57) scores than participants without SMI (Trails A: M = 35.86; 
Trials B: M = 85.11), and those with SMI showed lower clock drawing (M = 4.66) and category 
fluency (M = 19.11) than participants without SMI (clock drawing: M = 4.67; category fluency: 
M = 21.84), though these differences did not reach significant levels. Figure 20 displays scores 
by group for each EF neuropsychological assessment.
52 
 
             
             
Figure 20. Distribution of EF composite score, Trails A and B, clock drawing, and category fluency, by SMI group
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Memory domains. There was not a significant difference for SMI and nSMI patients 
on memory composite scores (F(1, 114) = .03, p = .866, ηp2 = .00). Additionally, no 
significant differences between SMI and nSMI groups were found for scores on RAVLT 
immediate recall (F(1, 114) = 1.04, p = .309, ηp2 = .01); RAVLT delayed recall (F(1, 115) = 
.43, p = .516, ηp2 = .00); Logical Memory I (F(1, 115) = .45, p = .505, ηp2 = .00); or Logical 
Memory II (F(1, 115) = .61, p = .436, ηp2 = .01). Comparing the estimated marginal means 
showed that those with SMI had higher memory composite scores (M = .84), higher RAVLT 
immediate recall scores (M = 10.48), and higher RAVLT delayed recall scores (M = 8.77), 
than participants without SMI (memory composite: M = .81; RAVLT immediate recall: M = 
9.64; RAVLT delayed recall: M = 8.16), though not to a significant level. However, while 
still not to a significant level, participants with SMI showed lower estimated marginal means 
for Logical Memory I (M = 15.97) and Logical Memory II (M = 14.74) than participants 
without SMI (Logical Memory I: M = 16.55; Logical Memory II: M = 15.47). Figure 21 
displays scores for each memory test.
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Figure 21. Distribution of Memory composite score, RAVLT, and WS-IV LM I and II, by SMI group
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Research Question II: Subjective Memory Complaint and Biomarker Level 
One-way ANCOVAs were conducted between SMI and nSMI groups to compare tau 
binding in the left and right entorhinal cortices and the left and right hippocampi, while 
controlling for possible confounding variables (gender, age, education, ethnicity, and APOE 
status). Levene’s test and normality checks were carried out and the assumptions met.  
Entorhinal cortices and SMI. There were no significant differences for SMI and 
nSMI participants in tau binding in the left entorhinal cortex (F(1, 115) = .02, p = .886, ηp2 = 
.00) or right entorhinal cortex (F(1, 115) = .02, p = .886, ηp2 = .00). Figures 22 and 23 show 
distribution of SUVR for left and right entorhinal regions, by SMI and nSMI group. 
 
 
Figure 22. Histogram showing distribution of left entorhinal SUVR, by group 
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Figure 23. Histogram showing distribution of right entorhinal SUVR, by group 
 
Hippocampi and SMI. There were no significant differences between SMI and nSMI 
groups in tau binding in the left (F(1, 115) = .16, p = .689, ηp2 = .00) or right (F(1, 115) = .15, 
p = .701, ηp2 = .00) hippocampi. Figures 24 and 25 show SMI and nSMI grouping 
distributions of SUVR for left and right hippocampi.   
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Figure 24. Histogram showing distribution of left hippocampus SUVR, by group 
 
 
Figure 25. Histogram showing distribution of right hippocampus SUVR, by group 
 
Research Question III: Subjective Memory Impairment, Tau Level, and 
Memory Measures 
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A two-way ANCOVA was conducted to determine if differences between SMI and 
nSMI groups in level of tau binding in the left and right entorhinal cortices and left and right 
hippocampi interacted with memory performance. Specifically, the neuropsychological 
memory domains included the memory composite, RAVLT immediate recall, RAVLT 
delayed recall, WMS-IV Logical Memory I, and WMS-IV Logical Memory II scores. 
Analyses for each domain were run separately. Gender, age, ethnicity, education, and APOE 
ɛ4 status were again used as covariates to control for individual differences. Preliminary 
checks were conducted to ensure that there were no violations of assumptions of normality, 
linearity, homogeneity of variances, homogeneity of regression slopes, and reliable 
measurement of the covariate.  
Memory composite. There was not a significant interaction effect for SMI and 
memory composite (F(1, 98) = 2.66, p = .106, ηp2 = .03) after adjusting for left entorhinal tau 
level. There were no main effects for SMI (F(1, 98) = .10, p = .757, ηp2 = .00) and when 
controlling for the B-H method, the main effect for left entorhinal tau level did not reach 
significance (F(1, 98) = 5.55, p = .021, ηp2 = .05). There was not a significant interaction 
effect for SMI and memory composite scores (F(1, 98) = .75, p = .390, ηp2 = .01) after 
adjusting for right entorhinal tau level. Again, neither main effect were statistically 
significant (SMI: F(1, 99) = 2.77, p = .099, ηp2 = .03; right entorhinal tau level: F(1, 98) = 
6.21, p = .014, ηp2 = .06). Estimated marginal means for memory composite scores, SMI, and 
entorhinal tau level are seen in Figures 26 and 27.  
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Figure 26. Line graph of memory composite estimated marginal means by SMI presence, 
when adjusting for left entorhinal tau level 
 
Figure 27. Line graph of memory composite estimated marginal means by SMI presence, 
when adjusting for right entorhinal tau level 
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There was not a significant interaction effect for SMI and memory composite (F(1, 
97) = 1.73, p = .191, ηp2 = .02) after adjusting for left hippocampus tau level. The main 
effects for SMI (F(1, 97) = .20, p = .654, ηp2 = .00) and left hippocampus tau level (F(1, 97) 
= 1.77, p = .186, ηp2 = .02) were not significant. There was not a significant interaction effect 
for SMI and memory composite (F(1, 97) = 1.51 p = .223, ηp2 = .02) after adjusting for right 
hippocampus tau level, and neither main effect for SMI (F(1, 97) = .30, p = .583, ηp2 = .00) 
or right hippocampus tau level (F(1, 97) = 1.26, p = .265, ηp2 = .01) were significant (see 
Figures 28 and 29).  
 
Figure 28. Line graph of memory composite estimated marginal means by SMI presence, 
when adjusting for left hippocampus entorhinal tau level 
 
 
61 
 
 
Figure 29. Line graph of memory composite estimated marginal means by SMI presence, 
when adjusting for right hippocampus entorhinal tau level 
 
RAVLT immediate recall. There was not a significant interaction effect for SMI and 
RAVLT immediate recall (F(1, 98) = 2.92, p = .091, ηp2 = .03) when adjusting for left 
entorhinal tau level. The main effect for SMI (F(1, 98) = .01, p = .943, ηp2 = .00) and left 
entorhinal tau level (F(1, 98) = 2.47, p = .119, ηp2 = .03) were not significant. For these same 
variables (SMI and RAVLT immediate recall), adjusting for right entorhinal tau level did not 
result in significant interaction effects (F(1, 98) = .33, p = .564, ηp2 = .00) or a main 
interaction effect for SMI (F(1, 98) = .45, p = .506, ηp2 = .01). After controlling via the B-H 
method, there was not a significant main effect for right entorhinal tau level and RAVLT 
immediate recall (F(1, 98) = 5.83, p = .018, ηp2 = .06; see Figures 30 and 31).  
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Figure 30. Line graph of RAVLT immediate recall estimated marginal means by SMI 
presence, when adjusting for left entorhinal tau level 
 
 
Figure 31. Line graph of RAVLT immediate recall estimated marginal means s by SMI 
presence, when adjusting for right entorhinal tau level 
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 There was not a significant interaction effect for SMI and RAVLT immediate recall 
(F(1, 97) = 2.09, p = .152, ηp2= .02) after adjusting for left hippocampus tau level. The main 
effect for SMI (F(1, 97) = .59, p = .446 ηp2 = .01) and for left hippocampus tau level (F(1, 
97) = .61, p = .437, ηp2 = .01) were not significant. Interaction (F(1, 97) = 1.18, p = .281, ηp2= 
.01) and main effects (SMI: F(1, 97) = .78, p = .379, ηp2 = .01; right hippocampus tau level 
F(1, 97) = .42, p = .520, ηp2 = .00) did not reach significance when adjusted for right 
hippocampus tau level.  Figures 32 and 33 show estimated marginal means for these effects.  
 
Figure 32. Line graph of RAVLT immediate recall estimated marginal means by SMI 
presence, when adjusting for left hippocampus tau level 
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Figure 33. Line graph of RAVLT immediate recall estimated marginal means by SMI 
presence, when adjusting for right hippocampus tau level 
 
RAVLT delayed recall.  There was not a significant interaction effect for SMI and 
RAVLT delayed recall (F(1, 99) = 1.72 p = .193, ηp2 = .02) after adjusting for left entorhinal 
tau level. The main effect for SMI (F(1, 99) = .15, p = .700, ηp2 = .00) was not significant, 
and the main effect for left entorhinal tau level (F(1, 99) = 5.37, p = .023, ηp2 = .05) did not 
survive the B-H method. There was not a significant interaction effect for SMI and RAVLT 
delayed recall (F(1, 99) = .15, p = . 702, ηp2 = .00) when adjusted for right entorhinal tau 
level. Again, the main effect for SMI (F(1, 99) = .68, p = .411, ηp2 = .01) was not significant, 
and the main effect for right entorhinal tau level (F(1, 99) = 8.36, p = .005, ηp2 = .08) did not 
survive the B-H method (see Figures 34 and 35). 
 
65 
 
 
Figure 34. Line graph of RAVLT delayed recall estimated marginal means by SMI presence, 
when adjusting for left entorhinal tau level 
 
 
 
Figure 35. Line graph of RAVLT delayed recall estimated marginal means by SMI presence, 
when adjusting for right entorhinal tau level 
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 There was not a significant interaction effect for SMI and RAVLT delayed recall 
(F(1, 98) = 2.77, p = .099, ηp2 = .03) after adjusting for left hippocampus tau level. The main 
effect for SMI was not significant (F(1, 98) = 1.03, p = .312, ηp2 = .01) and the main effect 
for left entorhinal tau level (F(1, 98) = 4.74, p = .032, ηp2 = .05), did not reach significance 
once the B-H method was applied (see Figure 36).  
There was not a significant interaction effect for SMI and RAVLT delayed recall 
(F(1, 98) = 2.33, p = .130, ηp2 = .02) after adjusting for right hippocampus tau level,. The 
main effect for SMI was not significant (F(1, 98) = 1.52, p = .221, ηp2 = .02) and the main 
effect for right hippocampus tau level (F(1, 98) = 5.13, p = .026, ηp2 = .05) did not survive 
application of the B-H method (see Figure 37). 
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Figure 36. Line graph of RAVLT delayed recall estimated marginal means by SMI presence, 
when adjusting for left hippocampus tau level 
 
 
Figure 37. Line graph of RAVLT delayed recall estimated marginal means by SMI presence, 
when adjusting for right hippocampus tau level 
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WMS-IV Logical Memory I. The interaction effect for SMI and Logical Memory I, 
when adjusted for left entorhinal tau level, was not significant (F(1, 99) = 6.48, p = .012, ηp2 
= .06) after the B-H method was applied. The main effect for SMI (F(1, 99) = .30, p = .587, 
ηp2 = .00) was not significant; however, the main effect for left entorhinal tau level (F(1, 99) 
=10.47, p = .002, ηp2 = .10) was significant and indicated a difference in Logical Memory I 
scores for low versus high levels of tau. There was not a significant interaction effect for SMI 
and Logical Memory I after adjusting for right entorhinal tau level (F(1, 99) = 3.47, p = .065, 
ηp2 = .03). The main effect for SMI (F(1, 99) = .07, p = .788, ηp2 = .00) was not significant. 
However, the main effect for right entorhinal tau level was significant (F(1, 99) = 15.93, p = 
.000, ηp2 = .14). Figures 38 and 39 show these effects.  
 
Figure 38. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI 
presence, when adjusting for left entorhinal tau level 
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Figure 39. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI 
presence, when adjusting for right entorhinal tau level 
When applying the B-H method, there was not a significant interaction effect for SMI 
and Logical Memory I after adjusting for left hippocampus tau level (F(1, 98) = 4.84, p = 
.030, ηp2 = .05). The main effect for SMI, F(1, 98) = .376, p = .541, ηp2 = .004, was not 
significant, however left hippocampus tau level (F(1, 98) = 10.03, p = .002, ηp2 = .09), was 
significant when utilizing B-H values. There was not a significant interaction effect (F(1, 98) 
= 4.69, p = .033, ηp2 = .05), after right hippocampus tau level adjustment, but there was a 
significant main effect for right hippocampus tau level (F(1, 98) = 10.13, p = .002, ηp2 = .09). 
There was no significant main effect for SMI (F(1, 98) = .46, p = .500, ηp2 = .01; see Figures 
40 and 41). 
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Figure 40. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI 
presence, when adjusting for left hippocampus tau level 
 
 
 
Figure 41. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI 
presence, when adjusting for right hippocampus tau level 
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WMS-IV Logical Memory II. There was not a significant interaction effect for SMI 
and Logical Memory II after adjustment for left entorhinal tau level (F(1, 99) = 6.69, p = 
.011, ηp2 = .06). The main effect for SMI was not significant (F(1, 99) = 2.46,  p = .120, ηp2 = 
.02). There was not a significant main effect for left entorhinal tau level (F(1,99) = 7.77, p = 
.006, ηp2 = .07). While there was no interaction effect (F(1, 99) = 2.94, p = .090, ηp2 = .03), 
after adjusting for right entorhinal tau level, there was a main effect for right entorhinal tau 
level (F(1, 99) = 11.52, p = .001, ηp2 = .10), after applying the B-H method, indicating a 
difference in Logical Memory II scores based on low versus high levels of tau in the right 
entorhinal cortex (see Figures 42 and 43).  
 
 
Figure 42. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI 
presence, when adjusting for left entorhinal tau level 
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Figure 43. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI 
presence, when adjusting for right entorhinal tau level 
Finally, there was not a significant interaction effect of SMI and Logical Memory II 
(F(1, 98) = 1.42, p = .237, ηp2 = .01) after adjusting for left hippocampus tau level. The main 
effect for SMI (F(1, 98) = .01, p = .920, ηp2 = .00) and left hippocampus tau level (F(1, 98) = 
6.09, p = .015, ηp2 = .06) was not significant. There was not a significant interaction effect for 
SMI and Logical Memory II after adjusting for right hippocampus tau level (F(1, 98) = 1.94, 
p = .167, ηp2 = .02). The main effect for SMI was not significant (F(1, 98) = .05, p = .820, ηp2 
= .00) and the main effect for right hippocampus tau level was not significant (F(1, 98) = 
6.74, p = .011, ηp2 = .06). Figures 44 and 45 depict the effects for these analyses.  
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Figure 44. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI 
presence, when adjusting for left hippocampus tau level 
 
 
 
Figure 45. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI 
presence, when adjusting for right hippocampus tau level  
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CHAPTER IV: DISCUSSION  
Findings 
The aims of the current study were threefold; First, I assessed neuropsychological 
functioning in a sample of clinically normal participants with and without SMI, to determine 
if there were differences between groups in the cognitive domains of executive function and 
memory. Second, I examined if level of tau AV-1451 binding in the hippocampi or 
entorhinal cortices differed between SMI and nSMI individuals. Finally, I determined if 
presence of SMI and level and location of tau AV-1451 binding in these regions revealed 
significant differences in memory performance between SMI and nSMI groups.  
Importantly, my participant pool did not differ in terms of demographic data (gender, 
ethnicity, age, or education level), or in APOE ɛ4 status. Though not found to be significantly 
different between groups, these possible confounding variables were included as covariates 
in all analyses, allowing for results to be as specific to my research questions as possible. To 
limit possible type I or type II errors, I employed a strict false discovery rate procedure, the 
Benjamini-Hochburg algorithm. From utilization of scientific analyses and stringent alpha 
levels, the resulting data and conclusions drawn are appropriate to the task of assessing 
mediation of SMI, neuropsychological functioning, and tau binding in a clinically normal 
sample.  
Overall, no differences were found between groups within the cognitive domains of 
executive functioning or memory when separated by SMI, in support of my first hypothesis. 
When analyzing levels of tau in the hippocampi and entorhinal cortices, no significant 
differences were found between groups, and did not support my second hypotheses. When 
separating groups by SMI and low/high levels of tau in each brain region, no significant 
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interaction effects were discovered. However, there were significant main effects for tau 
level and location (left/right entorhinal cortices and left/right hippocampi) for the Wechsler 
Memory Scale-IV Logical Memory I test, and in the left entorhinal cortex for Logical 
Memory II, supporting differences in level of AV-1451 tau binding for story memory in 
these regions. 
Executive functioning in SMI and nSMI groups. Data supported my first research 
question, which asserted participant performance in the domain of executive function would 
not differ between groups. Additionally, for each hypothesis within this research question, 
including assessing EF composite score as well as specific neuropsychological tests (e.g. 
Trails A and B, clock drawing, and category fluency), data showed there were no significant 
differences in any EF task between SMI or nSMI groups.  
Data supporting insignificant variability in EF between groups is an important 
consideration, given the underlying foundation of SMI. SMI, while varied in the literature, is 
commonly determined based solely on a single self-report question, which asks participants 
to reflect on their own view of changes in their memory (Abdulrab & Heun, 2008). Had 
participants differed in terms of executive functioning, an argument could be made that 
individuals are not at full capacity to be aware of or able to assess their own memory 
function (Stenfors, Marklund, Hanson, Theorell, & Nilsson, 2013). As my groups did not 
differ in EF performance, and did not show impaired EF as per the ADNI3 criteria for CN 
group selection, I concluded that my sample was capable of assessing their own memory 
changes. Current findings also support previous work which suggested individuals with 
memory changes which are not detectable by current neuropsychological assessment have 
insight into their own specific memory decline (Bäckman et al., 2005).  
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Memory in SMI and nSMI groups. Hypotheses within my first research question 
assessed memory functioning in SMI and nSMI groups. I anticipated that splitting the overall 
CN sample into SMI and nSMI groups would allow for discovery of specific differences 
between groups which would not be otherwise detectable. My hypotheses aimed to determine 
differences between groups on memory composite scores, as well as list learning (RAVLT 
immediate recall and RAVLT delayed recall) and story memory (WMS-IV Logical Memory 
I and Logical Memory II). I hypothesized there would be a significant difference between 
groups on each of these factors, with participants with SMI showing significantly worse 
memory scores than participants without SMI. Data showed no significant differences 
between groups on any memory tasks, leading to rejection of these hypotheses.  
Given the stringent requirements for cognitive impairment diagnosis by ADNI3 
criteria, it follows that performance for those determined to be cognitively normal, as in my 
sample group, may not vary enough to detect notable differences, even when separated by 
subjective impairment. While previous research supports SMI can be an early sign of MCI or 
AD development (Jessen et al., 2010), the current study did not find support for use of SMI 
alone as diagnostic tool to assess memory change independent of neuropsychological 
assessment.  
Additionally, it is possible individuals who were high functioning prior to onset of 
subjective memory difficulty may have had a decline in memory functioning, yet due to 
higher premorbid functioning, cognitive reserve, and ability to compensate for these changes, 
they fell in the average or “normal” range on testing (Stern, 2006). Thus, while these 
individuals may have a decline in their memory consistent with the early stages of 
neurocognitive decline leading to MCI or AD, it may not be to a level sensitive enough to 
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detect via neuropsychological measures or ADNI3 MCI criteria, and thus may have obscured 
the homogeneity of the current “cognitively normal” sample.  
Tau binding of AV-1451 in the entorhinal cortices and hippocampi. As previous 
research has shown, while NFTs have been implicated in MCI or AD involvement (Dickson, 
2004), so too is there a wealth of knowledge supporting tau as not solely specific to MCI or 
AD, with various other existing tauopathies in which tau accumulation affects functioning 
(Institute for Neurodegenerative Diseases, 2013). As AV-1451 is a newer biomarker which 
has shown to be specific to AD tau binding, my research expanded on those of Schöll et al. 
(2016), who found the AV-1451 biomarker related to impairment in global cognition in 
healthy controls. My study looked at memory, a hallmark early deficit in AD, and provided 
evidence that the AV-1451 biomarker may not significantly relate to memory in the 
entorhinal cortices or hippocampi in healthy controls, when grouped solely by SMI.  
Specifically, my second research question asked if binding of the tau AV-1451 
biomarker differed between SMI and nSMI groups. I assessed AV-1451 tau SUVRs in 
partial-volume corrected tau-PET imaging for each participant and analyzed binding in four 
regions of the brain: left entorhinal cortex, right entorhinal cortex, left hippocampus, and 
right hippocampus. My results did not detect differences in tau binding in any region 
assessed between SMI and nSMI groups. From this, I can conclude that similarly to my 
previous finding which showed presence of SMI is not specific enough to detect differences 
in memory scores, neither is it specifically related to differences in level of tau binding alone 
in the entorhinal cortices or hippocampi. Overall, level of tau related to SMI was not to a 
significant enough level to be detected or supported via the current research study.  
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Neuropsychological functioning and SMI, by level of tau AV-1451 binding. My 
final research question looked at SMI and level of tau binding to assess differences in 
neuropsychological performance and determine if these differences were mediated by level 
and location of AV-1451 binding.  
I hypothesized there would be significant differences between groups on memory 
performance as mediated by tau level, location, and SMI presence. While analyses did not 
show significant interaction effects for tau level and SMI on any memory measure, main 
effects for Logical Memory I were significant for all regions of interest (ROI), and the main 
effect for Logical Memory II and the right entorhinal cortex was significant.  
Specifically, Logical Memory I estimated marginal means in all ROIs (left and right 
entorhinal cortices and hippocampi) showed those with high AV-1451 tau binding had lower 
Logical Memory I scores, indicating worse performance was related to higher level of tau. 
Logical Memory II performance in participants with high level of binding of AV-1451 in the 
left entorhinal cortex showed overall lower estimated marginal means (i.e., worse 
performance) than did participants with low tau levels, indicating differences on this task are 
again related to tau level in the left entorhinal cortex. Thus, significant differences in Logical 
Memory I and II performances were associated with level of tau binding in the entorhinal 
cortices and hippocampi. 
Overall, though the first two research questions looking at differences between groups 
on memory performance and tau binding independently were not supported, the current 
findings indicated there is an effect of location and level of tau on Logical Memory I and II 
performance. This finding provides support that differences on story memory tasks can be 
seen when level of AV-1451 tau binding in the entorhinal cortices and the hippocampi are 
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included in assessment, though this finding is not mediated by presence or absence of SMI. It 
may be that group differences are too minute to detect solely by presence of tau or SMI 
alone, but that low or high tau levels provide data on differences in immediate recall of a 
story memory task. Logical memory has shown to be a useful diagnostic tool for memory 
impairment (Lezak et al., 2012) and the current findings showed significant effect of tau level 
on Logical Memory I and II performance. My research provides additional support for use of 
WMS-IV Logical Memory as a beneficial diagnostic tool for detection of differences in tau 
level for participants.  
Strengths 
The current research was one of the first to attempt to determine a relationship between the 
novel AV-1451 biomarker and neuropsychological performance among cognitively normal 
individuals with subjective memory impairment. The current study used a very strict false 
discovery rate, in order to prevent inaccurate statistical results. Additionally, I included all 
possible covariate in my analyses, utilizing all demographic variables as well as APOE Ɛ4 
status in every analysis. Though researchers do not always do so, including these covariates 
allowed for an even stricter assessment of the dependent variables in question. Current results 
show a relationship between level of tau and story memory scores, which provides 
researchers with support for further evaluation of story memory as a means of detecting tau 
level in cognitively normal older adults (Ricci et al., 2012). Further, the current research 
provides added evidence of contextual memory as a marker for tau level, which has widely 
been implicated in progression from MCI to AD (Maass et al., 2017).  
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Limitations 
The first limitation to this study is that of diversity of participants. The ADNI3 
database consists of a widely heterogenous participant group, with the current study sample 
comprised of predominantly Caucasian, well-educated participants. Additionally, I only 
assessed AV-1451 in two brain regions (bilaterally), which are largely related to memory 
changes in AD. While I describe support for level of tau and its relationship to specific 
neuropsychological assessments, these findings cannot be generalized to tau levels in other 
brain regions, or other tau biomarkers.   
Additional limitations to the current study are that of the small SMI group size, which 
impacted power of my analyses, and the unequal sample sizes between groups. A larger, 
more equivalent sample would help to increase power of each analysis and would facilitate 
ability for identification of more nuanced differences and variability between groups for the 
AV-1451 biomarker. Finally, the lack of a retrospective study limits my results. I cannot 
conclude that these findings will lead to accurate detection of participants who will go on to 
develop a neurodegenerative disorder, as I do not know which participants will develop MCI 
or AD.  
The current method for evaluating SMI followed previous research methodology, 
which utilized a yes/no question modality (Abdulrab & Heun, 2008). This measure may not 
have been sensitive or specific enough to complexly assess subjective memory impairment. I 
did not include additional collateral information to reinforce notable memory changes in day-
to-day life, which if utilized may have created a more stringent sample of SMI participants.  
Additionally, the current research only assessed two cognitive domains (EF and 
memory), and only memory was assessed in conjunction with tau and SMI concurrently. 
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Perhaps addition of other cognitive domains would have provided significant detection of 
differences between SMI and nSMI groups beyond what was currently found.  
Future directions and recommendations 
The current research provides a baseline for future researchers to utilize the cognitive 
measure of story memory in conjunction with tau level differences in the entorhinal cortices 
and hippocampi, with the aim of developing a neuropsychological profile for individuals who 
may benefit from earlier intervention to slow progression of neurodegenerative decline. 
Future research assessing these factors longitudinally in individuals who develop MCI or AD 
may elucidate findings.  
My method for defining SMI was in concordance with previous research and is a 
widely accepted method for measuring subjective change (Eliassen et al., 2017; Jessen et al., 
2010; Vogel et al., 2017); however, it is possible the question used was not specific or 
sensitive enough, and future research could include a more in-depth measure of subjective 
memory complaint. A robust subjective measure may more precisely classify participants in 
future research and may provide a more homogenous sample of individuals with changes in 
memory which are undetectable by neuropsychological assessments alone. Furthermore, 
inclusion of collateral information regarding memory change in conjunction with participant 
report would likely provide a stricter SMI sample for future studies.   
It would also be beneficial to employ retrospective research with participants who 
were CN at baseline testing, but later went on to develop AD. This would allow for the 
application of a known groups methodology and would allow for more directly relatable 
results to be discussed (e.g. Jones, Livner, & Bäckman, 2006.). Specifically, as it cannot be 
known if the current participants will go on to develop MCI or AD, retrospective research 
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utilizing data of individuals who were shown to have developed MCI or AD would allow for 
a sample specific to individuals who only displayed SMI prior to cognitive 
neurodegeneration. As well, re-running the current hypotheses in a different population, such 
as individuals with MCI, could provide added support for the connection between story 
memory and level of tau in the left and right entorhinal cortices and hippocampi regions. 
Moreover, research in a sample of individuals with MCI may further elucidate the 
relationship between tau and other neuropsychological domains. Research with participants 
currently diagnosed with MCI or AD would offer further support for use of SMI and 
biomarker AV-1451 as a link for neurodegenerative disorders and may provide support for 
level of tau binding and/or SMI presence to warrant implementation of intervention 
techniques to slow progression of neurodegeneration.  
The current research provides support for utilization of the Wechsler Memory Scale-
IV Logical Memory I and II subtests in regard to sensitivity for level of tau in the entorhinal 
cortices and hippocampi. Expanding testing of tau binding in additional neuroanatomic 
regions could allow for the relationship between SMI, cognitive functioning, and tau in other 
brain regions to be elucidated. As supported by research, such as that of Bäckman et al. 
(2005) and Chen et al. (2001), region-specific changes in functioning other than for memory 
have been seen in pre-clinical AD participants. Thus, continued research assessing these 
variations and how they may relate to SMI and memory is needed and further supported by 
the current research.    
Lastly, a larger sample overall would increase the power of the analyses and allow for 
detection of likely more nuanced differences. In addition, further equality in number of 
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participants between SMI and nSMI may positively influence the ability of the statistical 
analyses to detect more subtle differences within cognitively normal groups.  
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